Analytical Data
-
基因名
HLA-A*02:01&B2M&RHAMM-R3(ILSLELMKL) Monomer
- Application
-
别名
HLA-A*0201 & B2M & RHAMM-R3 (ILSLELMKL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&ILSLELMKL
-
分子量
40-44 kDa and 13 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules, playing a crucial role in immune response by presenting peptides to CD8+ T cells. Its importance in transplantation, autoimmunity, and cancer immunotherapy has spurred extensive research into its interactions with various peptide antigens. Beta-2-microglobulin (B2M) is an essential component of the HLA class I complex, stabilizing its structure and facilitating proper peptide loading. The peptide RHAMM-R3 (ILSLELMKL), derived from the receptor for hyaluronan-mediated motility (RHAMM), has garnered attention for its potential immunogenicity and role in tumor progression. The study of HLA-A*02:01 complexed with B2M and the RHAMM-R3 peptide, resulting in a monomeric recombinant protein, serves as a valuable tool for investigating T cell responses and the mechanisms of antigen presentation. This protein can be used in vaccine development and immunotherapy, as it may enhance the understanding of how specific peptides are recognized by the immune system. Furthermore, the structural and functional characterization of this recombinant protein can provide insights into the design of better immunotherapeutic strategies for tumors expressing RHAMM, as well as for other diseases where HLA-A*02:01 is implicated. This research represents a significant step in refining our approach to harnessing the immune system against cancer and improving patient outcomes.
